LondonHealthy people will take an experimental Alzheimer’s drug.
Participants feel fine but accept an unproven drug’s risks on a prediction.
Blood tests measuring p-tau217 predict decline decades early, turning risk into a measurable biomarker.
The phase III PrevenTRON trial will run four to six years.
How each outlet framed it
- The Guardian
- foregrounds p-tau217 biomarker's 78% predictive accuracy over 10 years and phase III PrevenTRON trial mechanism
Sources: The Guardian